Pictet Asset Management’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-30,230
Closed -$3.07M 2134
2025
Q4
$3.07M Buy
30,230
+2,880
+11% +$231K ﹤0.01% 850
2025
Q3
$1.5M Sell
27,350
-102
-0.4% -$5.1K ﹤0.01% 936
2025
Q2
$1.46M Sell
27,452
-60,009
-69% -$3.05M ﹤0.01% 936
2025
Q1
$3.79M Buy
87,461
+18,120
+26% +$918K ﹤0.01% 833
2024
Q4
$3.9M Buy
69,341
+1,609
+2% +$100K ﹤0.01% 845
2024
Q3
$4.61M Sell
67,732
-1,070
-2% -$60.4K 0.01% 810
2024
Q2
$2.91M Buy
68,802
+1,875
+3% +$103K ﹤0.01% 854
2024
Q1
$4.62M Buy
66,927
+1,012
+2% +$64K 0.01% 799
2023
Q4
$4.88M Sell
65,915
-10,251
-13% -$672K 0.01% 801
2023
Q3
$5.2M Buy
+76,166
New +$6.46M 0.01% 765

Other funds holding EXAS

Pictet Asset Management's EXAS Position: Q1 2026 in Review

Pictet Asset Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 30,230 shares — an estimated $3.07M sold.

Pictet Asset Management first reported a position in EXAS in Q3 2023 and held it in 10 quarters. The position peaked at $5.2M in Q3 2023. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Pictet Asset Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Pictet Asset Management sold 30,230 Exact Sciences shares in Q1 2026, an estimated $3.07M.
  • Pictet Asset Management first reported a position in Exact Sciences in Q3 2023 and held it in 10 quarters.
  • Pictet Asset Management's Exact Sciences position peaked at $5.2M in Q3 2023.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.